This study examined data from the FDA, Japanese, and WHO databases covering reports from 2004 to 2024. Researchers looked at 50 different medications, including finasteride and diltiazem, to see if they were linked to cognitive disorders in vulnerable populations like children and seniors. They found significant signals for these issues across the board. Importantly, 74% of these 50 medications did not currently have warnings on their FDA labels regarding cognitive disorders. The findings were consistent across all three different international databases for 92% of the drug-event pairs checked.
The study focused on statistical associations found in adverse event reports, not on proving that these drugs cause these problems directly. Factors like early reporting patterns or random failures were also considered when looking at the data. The main reason to be careful is that many patients in high-risk groups might not have current warnings for these potential side effects. This gap between the data and existing labels suggests a need for further research and possible updates to drug information.
Readers should understand that this study shows a link based on reporting patterns, not a confirmed cause-and-effect relationship. The results indicate a need for increased clinical awareness, especially when treating children and older adults. Further research is required before any definitive conclusions about safety can be drawn. Patients should talk to their healthcare providers about any concerns regarding their medications.
